Cargando…
Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation
BACKGROUND: The utilization of oocyte cryopreservation (OC) has become popularized with increasing numbers of reproductive-aged patients desiring to maintain fertility for future family building. OC was initially used for fertility preservation in postmenarchal patients prior to gonadotoxic therapie...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740039/ https://www.ncbi.nlm.nih.gov/pubmed/34996479 http://dx.doi.org/10.1186/s12958-021-00884-0 |
_version_ | 1784629228700958720 |
---|---|
author | Walker, Zachary Lanes, Andrea Ginsburg, Elizabeth |
author_facet | Walker, Zachary Lanes, Andrea Ginsburg, Elizabeth |
author_sort | Walker, Zachary |
collection | PubMed |
description | BACKGROUND: The utilization of oocyte cryopreservation (OC) has become popularized with increasing numbers of reproductive-aged patients desiring to maintain fertility for future family building. OC was initially used for fertility preservation in postmenarchal patients prior to gonadotoxic therapies; however, it is now available to patients to circumvent age-related infertility and other diagnoses associated with early loss of ovarian reserve. The primary aim of this paper is to provide a narrative review of the most recent and robust data on the utilization and outcomes of OC in both patient populations. SUMMARY: OC results in similar oocyte yield in patients facing gonadotoxic therapies and patients undergoing planned OC. Available data are insufficient to predict the live birth rates or the number of oocytes needed to result in live birth. However, oocyte yield and live birth rates are best among patients < 37.5 years old or with anti-mullerian hormone levels > 1.995 ng/dL, at the time of oocyte retrieval. There is a high ‘no use’ rate (58.9%) in patients using planned OC with 62.5% returning to use frozen oocytes with a spouse. The utilization rate in medical OC patients is < 10%. There is currently no data on the effects of BMI, smoking, or ethnicity on planned OC outcomes. CONCLUSION: It is too early to draw any final conclusions on outcomes of OC in medical OC and planned OC; however, preliminary data supports that utilization of OC in both groups result in preservation of fertility and subsequent live births in patients who return to use their cryopreserved eggs. Higher oocyte yield, with fewer ovarian stimulation cycles, and higher live birth rates are seen in patients who seek OC at younger ages, reinforcing the importance of age on fertility preservation. More studies are needed in medical OC and planned OC to help guide counseling and decision-making in patients seeking these services. |
format | Online Article Text |
id | pubmed-8740039 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87400392022-01-07 Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation Walker, Zachary Lanes, Andrea Ginsburg, Elizabeth Reprod Biol Endocrinol Review BACKGROUND: The utilization of oocyte cryopreservation (OC) has become popularized with increasing numbers of reproductive-aged patients desiring to maintain fertility for future family building. OC was initially used for fertility preservation in postmenarchal patients prior to gonadotoxic therapies; however, it is now available to patients to circumvent age-related infertility and other diagnoses associated with early loss of ovarian reserve. The primary aim of this paper is to provide a narrative review of the most recent and robust data on the utilization and outcomes of OC in both patient populations. SUMMARY: OC results in similar oocyte yield in patients facing gonadotoxic therapies and patients undergoing planned OC. Available data are insufficient to predict the live birth rates or the number of oocytes needed to result in live birth. However, oocyte yield and live birth rates are best among patients < 37.5 years old or with anti-mullerian hormone levels > 1.995 ng/dL, at the time of oocyte retrieval. There is a high ‘no use’ rate (58.9%) in patients using planned OC with 62.5% returning to use frozen oocytes with a spouse. The utilization rate in medical OC patients is < 10%. There is currently no data on the effects of BMI, smoking, or ethnicity on planned OC outcomes. CONCLUSION: It is too early to draw any final conclusions on outcomes of OC in medical OC and planned OC; however, preliminary data supports that utilization of OC in both groups result in preservation of fertility and subsequent live births in patients who return to use their cryopreserved eggs. Higher oocyte yield, with fewer ovarian stimulation cycles, and higher live birth rates are seen in patients who seek OC at younger ages, reinforcing the importance of age on fertility preservation. More studies are needed in medical OC and planned OC to help guide counseling and decision-making in patients seeking these services. BioMed Central 2022-01-07 /pmc/articles/PMC8740039/ /pubmed/34996479 http://dx.doi.org/10.1186/s12958-021-00884-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Walker, Zachary Lanes, Andrea Ginsburg, Elizabeth Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation |
title | Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation |
title_full | Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation |
title_fullStr | Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation |
title_full_unstemmed | Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation |
title_short | Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation |
title_sort | oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740039/ https://www.ncbi.nlm.nih.gov/pubmed/34996479 http://dx.doi.org/10.1186/s12958-021-00884-0 |
work_keys_str_mv | AT walkerzachary oocytecryopreservationreviewoutcomesofmedicaloocytecryopreservationandplannedoocytecryopreservation AT lanesandrea oocytecryopreservationreviewoutcomesofmedicaloocytecryopreservationandplannedoocytecryopreservation AT ginsburgelizabeth oocytecryopreservationreviewoutcomesofmedicaloocytecryopreservationandplannedoocytecryopreservation |